Savara (SVRA) Depreciation & Amortization (CF) (2010 - 2026)
Savara's (SVRA) quarterly Depreciation & Amortization (CF) came in at $24000.0 in Q1 2026, down 20.0% year-on-year from $30000.0 in Q1 2025, and up 318.18% on a QoQ basis from -$11000.0 in Q4 2025.
Savara (SVRA) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $24000.0 in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 20.0% year-over-year to $24000.0 in Q1 2026; TTM through Mar 2026 was $81000.0, a 36.72% decrease from a year earlier, with the FY2025 full-year figure at $87000.0, down 33.08% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $24000.0, up from -$11000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for SVRA reached as high as $35000.0 in Q3 2025 and fell as low as -$11000.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $20588.2 across 5 years, with a median of $30000.0 in 2023.
- Across the five-year window, Depreciation & Amortization (CF) surged 357.14% in 2023 and sank 134.38% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $7000.0 in 2022, then surged by 357.14% to $32000.0 in 2023, then changed by 0.0% to $32000.0 in 2024, then sank by 134.38% to -$11000.0 in 2025, then jumped by 318.18% to $24000.0 in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $24000.0 in Q1 2026, -$11000.0 in Q4 2025, and $35000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | 24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24,000.00 |
| Mar 31, 2026 | 24,000.00 |
| Dec 31, 2025 | -11,000.00 |
| Dec 31, 2025 | -11,000.00 |
| Sep 30, 2025 | 35,000.00 |
| Sep 30, 2025 | 35,000.00 |
| Jun 30, 2025 | 33,000.00 |
| Jun 30, 2025 | 33,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Dec 31, 2023 | 32,000.00 |